Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$38.20 +3.7%	$36.66	$23.42 ▼ $62.58	$2.22B	0.8	706,821 shs	460,883 shs
OCUL Ocular Therapeutix	$12.13 +1.4%	$10.78	$5.78 ▼ $12.91	$2.11B	1.49	1.80 million shs	1.35 million shs
TARS Tarsus Pharmaceuticals	$56.56 +2.1%	$43.20	$25.14 ▼ $57.28	$2.39B	0.79	663,750 shs	705,632 shs
TRML Tourmaline Bio	$23.06 +2.7%	$19.25	$11.56 ▼ $29.79	$592.30M	2.04	287,717 shs	110,600 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+1.66%	+0.57%	-7.77%	+24.43%	-17.94%
OCUL Ocular Therapeutix	-1.48%	-4.32%	+3.82%	+65.65%	+35.29%
TARS Tarsus Pharmaceuticals	+3.18%	+5.10%	+31.37%	+28.95%	+111.25%
TRML Tourmaline Bio	+0.40%	+1.08%	+23.20%	+47.09%	+56.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.2941 of 5 stars	3.4	2.0	4.3	2.7	0.8	1.9
OCUL Ocular Therapeutix	4.0529 of 5 stars	3.5	3.0	4.1	2.7	1.7	0.0
TARS Tarsus Pharmaceuticals	1.8472 of 5 stars	2.5	1.0	0.0	3.3	2.5	0.6
TRML Tourmaline Bio	2.393 of 5 stars	3.5	2.0	0.0	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	47.47% Upside
OCUL Ocular Therapeutix	3.00	Buy	$17.20	41.80% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	17.87% Upside
TRML Tourmaline Bio	3.00	Buy	$50.14	117.45% Upside

Current Analyst Ratings Breakdown

Latest TRML, TARS, OCUL, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00
8/14/2025	TRML Tourmaline Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
8/6/2025	OCUL Ocular Therapeutix	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$22.00 ➝ $20.00
8/5/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $15.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
6/2/2025	TARS Tarsus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/27/2025	TARS Tarsus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$72.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$40.88M	54.30	N/A	N/A	$23.57 per share	1.62
OCUL Ocular Therapeutix	$63.72M	33.12	N/A	N/A	$1.76 per share	6.89
TARS Tarsus Pharmaceuticals	$182.95M	13.05	N/A	N/A	$7.88 per share	7.18
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$10.09 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.47	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
OCUL Ocular Therapeutix	-$193.51M	-$1.28	N/A	N/A	N/A	-382.51%	-71.92%	-49.36%	N/A
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.33	N/A	N/A	N/A	-31.13%	-32.36%	-21.04%	N/A
TRML Tourmaline Bio	-$73.21M	-$3.43	N/A	N/A	N/A	N/A	-30.50%	-29.63%	11/6/2025 (Estimated)

Latest TRML, TARS, OCUL, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	TRML Tourmaline Bio	-$0.94	-$0.90	+$0.04	-$0.90	N/A	N/A
8/6/2025	Q2 2025	TARS Tarsus Pharmaceuticals	-$0.33	-$0.48	-$0.15	-$0.48	$95.81 million	$102.66 million
8/5/2025	Q2 2025	OCUL Ocular Therapeutix	-$0.35	-$0.39	-$0.04	-$0.39	$13.12 million	$13.46 million
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
OCUL Ocular Therapeutix	0.23	10.10	10.02
TARS Tarsus Pharmaceuticals	0.22	5.26	5.21
TRML Tourmaline Bio	N/A	24.68	24.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
OCUL Ocular Therapeutix	59.21%
TARS Tarsus Pharmaceuticals	90.01%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
OCUL Ocular Therapeutix	2.30%
TARS Tarsus Pharmaceuticals	8.97%
TRML Tourmaline Bio	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.60 million	Optionable
OCUL Ocular Therapeutix	230	173.99 million	169.99 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.21 million	38.43 million	Optionable
TRML Tourmaline Bio	44	25.69 million	22.35 million	Optionable

TRML, TARS, OCUL, and AGIO Headlines

Recent News About These Companies

Analysts Set Expectations for Tourmaline Bio FY2025 Earnings

August 19 at 2:29 AM | marketbeat.com

FY2025 EPS Estimates for Tourmaline Bio Lowered by Analyst

August 19 at 2:17 AM | americanbankingnews.com

Tourmaline Bio Q3 EPS Forecast Raised by Leerink Partnrs

August 19 at 2:39 AM | marketbeat.com

Lifesci Capital Expects Higher Earnings for Tourmaline Bio

August 19 at 2:39 AM | marketbeat.com

What is Wedbush's Forecast for Tourmaline Bio Q3 Earnings?

August 19 at 2:39 AM | marketbeat.com

Leerink Partnrs Expects Higher Earnings for Tourmaline Bio

August 19 at 2:16 AM | americanbankingnews.com

Tourmaline Bio Q3 EPS Estimate Raised by Lifesci Capital

August 19 at 2:16 AM | americanbankingnews.com

Wedbush Estimates Tourmaline Bio's Q3 Earnings (NASDAQ:TRML)

August 18 at 2:43 AM | americanbankingnews.com

Tourmaline Bio (NASDAQ:TRML) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

August 17, 2025 | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Receives "Buy" Rating from Chardan Capital

August 16, 2025 | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Receives Buy Rating from Guggenheim

August 16, 2025 | marketbeat.com

Brokerages Set Tourmaline Bio, Inc. (NASDAQ:TRML) Target Price at $49.33

August 16, 2025 | americanbankingnews.com

Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know

August 15, 2025 | zacks.com

Tourmaline Bio (NASDAQ:TRML) Receives Buy Rating from Chardan Capital

August 15, 2025 | americanbankingnews.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Given Consensus Recommendation of "Buy" by Brokerages

August 14, 2025 | marketbeat.com

Tourmaline Bio Reports Positive Trial Results and Strong Cash Position

August 13, 2025 | tipranks.com

Tourmaline Bio, Inc.: Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 13, 2025 | finanznachrichten.de

Tourmaline Bio reports Q2 EPS (90c), consensus (93c)

August 13, 2025 | msn.com

Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 13, 2025 | globenewswire.com

Tourmaline Bio (TRML) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Position Boosted by Federated Hermes Inc.

August 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRML, TARS, OCUL, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$38.20 +1.38 (+3.75%)

Closing price 04:00 PM Eastern

Extended Trading

$38.20 +0.00 (+0.00%)

As of 05:13 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Ocular Therapeutix NASDAQ:OCUL

$12.13 +0.17 (+1.42%)

Closing price 04:00 PM Eastern

Extended Trading

$12.13 0.00 (0.00%)

As of 04:30 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Tarsus Pharmaceuticals NASDAQ:TARS

$56.56 +1.15 (+2.08%)

Closing price 04:00 PM Eastern

Extended Trading

$56.54 -0.02 (-0.04%)

As of 05:54 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tourmaline Bio NASDAQ:TRML

$23.06 +0.60 (+2.67%)

Closing price 04:00 PM Eastern

Extended Trading

$22.54 -0.51 (-2.23%)

As of 04:41 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time